证券日报网讯永安药业（002365）9月3日在互动平台回答投资者提问时表示，截至2025年8月29日，公 司股东人数为59，210户。 ...

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

Group 1 - Chengdu Huamei's 4-channel 12-bit 40G high-precision RF direct ADC chip has not yet achieved large-scale sales, with only sample deliveries and intention orders, indicating market demand uncertainty and potential risks [3] - Hason Co. plans to establish a joint venture company with a registered capital of 100 million yuan, in which it will hold a 10% stake, focusing on robot components and related technical services [4] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., with a minimum transfer price of 151 million yuan [5] Group 2 - Dechuang Environmental plans to delay its response to an inquiry letter from the Shanghai Stock Exchange by no more than 5 trading days to ensure accuracy and completeness [6] - Yong'an Pharmaceutical's actual controller and chairman Chen Yong has had his detention lifted, allowing him to resume his duties, with the company's operations reported as normal [7] - Western Gold has seen a stock price increase of 39.01% since August 29, amidst high market interest in gold, while the Shanghai Composite Index has decreased by 0.78% [8] Group 3 - Spring Xing Precision's recent operational environment remains stable, with no significant changes reported, and no undisclosed major matters by its controlling shareholder [9] - Hainan Rubber expects a reduction of approximately 2,500 tons in dry rubber production due to Typhoon "Swordfish," with damage to about 28,000 mu of rubber plantation [10][11] - Hangzhou High-tech has completed the transfer of 19.03% of its shares to Beijing Jirong Weiye Energy Technology Co., changing its controlling shareholder [12] Group 4 - Zheng Fengshou, the deputy general manager of Zhengyuan Dixin, has unfortunately passed away, with no stock holdings or unfulfilled commitments reported [13] - Changyuan Power's electricity generation in August was 3.771 billion kWh, a decrease of 6.03% year-on-year, with total generation from January to August down by 1.91% [15] - Shareholder Chen Dekang of Shapu Aisi plans to reduce his stake by up to 2% within three months through trading methods [17] Group 5 - Shankai Intelligent has won a procurement project for metering instruments with a bid amount of 13.318 million yuan [19]

Core Viewpoint - Yong'an Pharmaceutical (002365) announced that its actual controller and chairman, Chen Yong, has had the detention measures lifted by the Hekou County Supervisory Committee, allowing him to resume his duties as chairman of the company [1] Company Summary - The company has confirmed that Chen Yong is now able to perform his responsibilities as chairman, indicating a return to normalcy in its operations [1] - Chen Zidong will no longer act as the interim chairman, as Chen Yong has resumed his role [1]

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) announced that its actual controller and chairman, Mr. Chen Yong, has had the detention measures lifted by the Hekou County Supervisory Committee, allowing him to resume his duties as chairman of the company [1] Company Operations - The company is currently operating normally following the lifting of the detention measures against Mr. Chen Yong [1] - Mr. Chen Zidong will no longer act on behalf of Mr. Chen Yong as the chairman [1]

Core Points - The actual controller and chairman of the company, Chen Yong, was previously under investigation by the Hefeng County Supervisory Committee, which has now been lifted, allowing him to resume his duties [1] Company Situation - The company announced that Chen Yong was placed under investigation on May 6, and the recent notification from his family indicates that the supervisory measures have been removed [1] - The company’s production and operational status is reported to be normal following the resolution of the investigation [1]

智通财经APP讯，永安药业(002365.SZ)公告，公司实际控制人、董事长陈勇先生此前被鹤峰县监察委员 会立案调查并实施留置。近日，公司收到陈勇先生家属的通知，其收到鹤峰县监察委员会出具的《解除 留置通知书》，鹤峰县监察委员会已解除对陈勇先生的留置措施。 ...

特此公告。 潜江永安药业股份有限公司 潜江永安药业股份有限公司（以下简称"公司"）于 2025 年 5 月 6 日披露 《关于公司实际控制人、董事长被留置的公告》（公告编号：2025-31），公司 实际控制人、董事长陈勇先生被鹤峰县监察委员会立案调查并实施留置。 近日，公司收到陈勇先生家属的通知，其收到鹤峰县监察委员会出具的《解 除留置通知书》，鹤峰县监察委员会已解除对陈勇先生的留置措施。目前，陈勇 先生已能正常履行公司董事长的职责，公司生产经营情况正常。陈子笛先生将不 再代为履行公司董事长的职责。 证券代码：002365 证券简称：永安药业 公告编号：2025-50 公司指定信息披露媒体为《证券时报》、《中国证券报》、《上海证券报》 和巨潮资讯网，公司发布的信息均以在上述媒体刊登的公告为准。敬请广大投资 者注意投资风险。 关于公司实际控制人、董事长解除留置的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司 董 事 会 二〇二五年九月三日 ...

永安药业（002365）(002365.SZ)公告，公司实际控制人、董事长陈勇先生此前被鹤峰县监察委员会立 案调查并实施留置。近日，公司收到陈勇先生家属的通知，其收到鹤峰县监察委员会出具的《解除留置 通知书》，鹤峰县监察委员会已解除对陈勇先生的留置措施。 ...

Core Viewpoint - The performance of the Zhongzheng 2000 ETF Enhanced (159556) has shown a decline of 2.20% as of the midday close on September 2, with a trading volume of 2.0863 million yuan [1] Group 1: Fund Performance - The Zhongzheng 2000 ETF Enhanced (159556) has a performance benchmark based on the Zhongzheng 2000 Index return [1] - Since its establishment on December 27, 2023, the fund has achieved a return of 18.85% [1] - The fund's return over the past month is reported at 9.45% [1] Group 2: Major Holdings - Major stocks in the fund include: - Zhenhua New Materials, down 1.72% - Hengbao Co., down 8.57% - Yongding Co., down 6.21% - Yong'an Pharmaceutical, down 2.03% - Xuguang Electronics, down 1.07% - Zhongke Technology, down 1.89% - Juguang Technology, down 3.61% - Huitong Energy, down 2.42% - Xinke Materials, down 2.41% - Batian Co., down 3.71% [1]